Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gastrointestinal stromal tumour – Share XBlueprint pays the price of Ayvakit phase 3 miss as FDA rejects drughttps://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/
